References

• Allen, A. et al. (2001). ‘Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.45.2.540- 545.2001.
• Allen, B. W. et al. (1983). 'Amikacin in the treatment of pulmonary tuberculosis', Tubercle. doi: 10.1016/0041-3879(83)90035-1.
• B., B. & P.C., A. (2004). 'Oxazolidinones: Activity, mode of action, and mechanism of resistance', International Journal of Antimicrobial Agents.
• Barry, C., Boshoff, H. & Dowd, C. (2005). 'Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis', Current Pharmaceutical Design. doi: 10.2174/1381612043383214.
• Bemer-Melchior, P., Bryskier, A. & Drugeon, H. B. (2000). ‘Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex', Journal of Antimicrobial Chemotherapy. doi: 10.1093/jac/46.4.571.
• Brennan, P. J. & Nikaido, H. (1995). 'The envelope of mycobacteria', Annual Review of Biochemistry. doi: 10.1146/annurev.bi.64.070195.000333.
• Brode, S. K. et al. (2015). ‘Multidrug-resistant tuberculosis: Treatment and outcomes of 93 patients', Canadian Respiratory Journal. doi: 10.1155/2015/359301
• Brogden, R. N. & Fitton, A. (1994). ‘Rifabutin: A Review of its Antimicrobial Activity, Pharmacokinetic Properties and Therapeutic Efficacy' Drugs. doi: 10.2165/00003495- 199447060-00008.
• Cambau, E. & Drancourt, M. (2014). ‘Steps towards the discovery of Mycobacterium tuberculosis by Robert Koch, 1882', Clinical Microbiology and Infection. doi: 10.1111/1469-0691.12555.
• Campbell, E. A. et al. (2001).'Structural mechanism for rifampicin inhibition of bacterial RNA polymerase', Cell. doi: 10.1016/S0092- 8674(01)00286-0.
• Catanzaro, A. et al. (2015). 'Performance comparison of three rapid tests for the diagnosis of drug- resistant tuberculosis', PLoS ONE. doi: 10.1371/journal.pone.0136861.
• CDC. (2018) Tuberculosis (TB) Disease: Symptoms and Risk Factors, Centers for Disease Control and Prevention. CDC, C. for disease control and prevention (2012). 'TB Elimination (Multidrug- Resistant Tuberculosis (MDR TB))', Cdc.
• Coyle, E. A., Kaatz, G. W. & Ryba, M. J. (2001). 'Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.45.6.1654- 1659.2001.
• Van Crevel, R., Ottenhoff, T. H. M., & Van Der Meer, J. W. M. (2002). 'Innate immunity to tuberculosis', Clinical Microbiology Reviews.
• Daniel, T. M. (2006) 'The history of tuberculosis', Respiratory Medicine. doi: 10.1016/j.rmed.2006.08.006.
• Daporta, M. T. et al. (2004). 'In vitro activity of older and newer fluoroquinolones against efflux- mediated high-level ciprofloxacin-resistant Streptococcus pneumoniae', International Journal of Antimicrobial Agents. doi: 10.1016/j.ijantimicag.2004.01.012.
• Davis, K. K. et al. (2007). 'Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: An observational case series', BMC Pulmonary Medicine. doi: 10.1186/1471-2466- 7-2.
• Desai, C. R. et al. (1989). 'Role of metronidazole in improving response and specific drug sensitivity in advanced pulmonary tuberculosis.', The Journal of the Association of Physicians of India.
• Dheda, K. et al. (2005). 'Lung remodeling in pulmonary tuberculosis', Journal of Infectious Diseases. doi: 10.1086/444545.
• Dick, T. (2001). 'Dormant tubercle bacilli: The key to more effective TB chemotherapy [3]', Journal of Antimicrobial Chemotherapy. doi: 10.1093/jac/47.1.117.
• Ducasse-Cabanot, S. et al. (2004). 'In Vitro Inhibition of the Mycobacterium tuberculosis β-Ketoacyl- Acyl Carrier Protein Reductase MabA by Isoniazid', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.48.1.242- 249.2004.
• Feklistov, A. et al. (2008). ‘Rifamycins do not function by allosteric modulation of binding of Mg 2 to the RNA polymerase active center', Proceedings of the National Academy of Sciences of the United States of America. doi: 10.1073/pnas.0802822105.
• Fischer, B., & Ferlinz, R. (1995). 'Therapy and prognosis of tuberculosis', Versicherungsmedizin / herausgegeben von Verband der Lebensversicherungs- Unternehmen e.V. und Verband der Privaten Krankenversicherung e.V.
• Frith, J. (2014). 'History of tuberculosis. Part 1 - Phthisis, consumption and the white plague', Journal of Military and Veterans' Health.
• Goering, R. V. et al. (2019). MIMS Medical Microbiology and Immunology, Journal of Visual Languages & Computing.
• Hu, Y., Coates, A. R. M., & Mitchison, D. A. (2003). 'Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.47.2.653-657.2003.
• Kawatsu, L., & Uchimura, K. (2016). 'Tuberculosis annual report 2014 -(1) Summary of statistics on tuberculosis notification and foreign-born tuberculosis patients', Kekkaku.
• Keung, A. et al. (1999) ‘Single and multiple dose pharmacokinetics of rifapentine in man: Part II', International Journal of Tuberculosis and Lung Disease.
• Leung, A. N. (1999). 'Pulmonary tuberculosis: The essentials', Radiology. doi: 10.1148/radiology.210.2.r99ja34307.
• Levinson, W. (2014). Review of Medical Microbiology and Immunology, The effects of brief mindfulness intervention on acute pain experience: An examination of individual difference.
• Merle, C. S. et al. (2014) ‘A Four-Month Gatifloxacin- Containing Regimen for Treating Tuberculosis', New England Journal of Medicine. doi: 10.1056/nejmoa1315817.
• Milatovic, D. et al. (2000). 'In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.44.4.1102- 1107.2000.
• Moghazeh, S. L. et al. (1996). ‘Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations', Antimicrobial Agents and Chemotherapy. doi: 10.1128/aac.40.11.2655.
• Mor, N. et al. (1995). 'Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.39.9.2073.
• Murugasu-Oei, B. and Dick, T. (2000). ‘Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG', Journal of Antimicrobial Chemotherapy. doi: 10.1093/jac/46.6.917.
• Pestova, E. et al. (2000) ‘Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones', Journal of Antimicrobial Chemotherapy. doi: 10.1093/jac/45.5.583.
• Prevention, C., & for, D. C., (2013). 'Core Curriculum on Tuberculosis : What the Clinician Should Know', Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination.
• Quemard, A., Lacave, C., & Laneelle, G. (1991). ‘Isoniazid inhibition of mycolic acid synthesis by cell extracts of sensitive and resistant strains of Mycobacterium aurum', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.35.6.1035.
• Ramaswamy, S., & Musser, J. M. (1998). ‘Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update', Tubercle and Lung Disease. doi: 10.1054/tuld.1998.0002.
• Rouse, D. A. et al. (1995). 'Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.39.11.2472.
• Rozwarski, D. A. et al. (1998). 'Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis', Science. doi: 10.1126/science.279.5347.98.
• Ruiz-Serrano, M. J. et al. (2000). 'In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs', Antimicrobial Agents and Chemotherapy. doi: 10.1128/AAC.44.9.2567-2568.2000.
• Schlünzen, F. et al. (2004). 'Inhibition of peptide bond formation by pleuromutilins: The structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin', Molecular Microbiology. doi: 10.1111/j.1365-2958.2004.04346.x.
• Scior, T. et al. (2002). 'Antitubercular isoniazid and drug resistance of Mycobacterium tuberculosis - A review', Archiv der Pharmazie. doi: 10.1002/ardp.200290005.
• Shoen, C. M., DeStefano, M. S., & Cynamon, M. H. (2000). ‘Durable cure for tuberculosis: Rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection', Clinical Infectious Diseases. doi: 10.1086/313876.
• Slayden, R. A., & Barry, C. E. (2000). ‘The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis', Microbes and Infection. doi: 10.1016/S1286- 4579(00)00359-2.
• Stover, C. K. et al. (2000). 'A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis', Nature. doi: 10.1038/35016103.
• du Toit, L. C., Pillay, V., & Danckwerts, M. P. (2006). 'Tuberculosis chemotherapy: Current drug delivery approaches', Respiratory Research. doi: 10.1186/1465-9921-7-118.